Advertisement

ADVERTISEMENT

Jolynn Tumolo

News
Sustained Improvements in QoL in Patients With AD Treated With Dupilumab
06/25/2021
"Dupilumab treatment (monotherapy or + TCS) provides rapid, significant, sustained improvements in signs, symptoms, and quality of life in patients with moderate-to-severe AD compared with control, regardless of prior systemic NSISS use,"...
"Dupilumab treatment (monotherapy or + TCS) provides rapid, significant, sustained improvements in signs, symptoms, and quality of life in patients with moderate-to-severe AD compared with control, regardless of prior systemic NSISS use,"...
"Dupilumab treatment...
06/25/2021
First Report Managed Care
News
Air Pollutant Appears to Increase Risk of Parkinson Disease
08/05/2021
“This finding suggests the role of air pollutants in Parkinson disease development, advocating for the need to implement a targeted public health policy,” researchers advised.
“This finding suggests the role of air pollutants in Parkinson disease development, advocating for the need to implement a targeted public health policy,” researchers advised.
“This finding suggests the role...
08/05/2021
Annals of Long-Term Care
News
Mislabeling of Drug Autoinjector Prompts Recall
09/03/2021
A labeling error has prompted Eli Lilly & Company to recall a prescription medication used to help control high blood sugar in people with type 2 diabetes.
A labeling error has prompted Eli Lilly & Company to recall a prescription medication used to help control high blood sugar in people with type 2 diabetes.
A labeling error has prompted...
09/03/2021
Pharmacy Learning Network
News
Family Engagement in ADHD Treatment Unfolds in 6 Stages, Study Suggests
10/01/2021
Based on in-depth interviews with 41 parents, researchers at Boston Medical Center have identified a 6-stage framework that describes the process of engaging in care for a child’s attention-deficit/hyperactivity disorder (ADHD).
Based on in-depth interviews with 41 parents, researchers at Boston Medical Center have identified a 6-stage framework that describes the process of engaging in care for a child’s attention-deficit/hyperactivity disorder (ADHD).
Based on in-depth interviews...
10/01/2021
Psych Congress Network
News
Initiation of ADHD Medication Does Not Require Higher Antidepressant Dose in Adults
10/27/2021
Over 6 months of follow-up, patients who initiated medication for ADHD while already taking antidepressants continued taking antidepressant medication at rates and dosages similar to patients not diagnosed with ADHD, according to study...
Over 6 months of follow-up, patients who initiated medication for ADHD while already taking antidepressants continued taking antidepressant medication at rates and dosages similar to patients not diagnosed with ADHD, according to study...
Over 6 months of follow-up,...
10/27/2021
Psych Congress Network
News
Treatment Outperforms Placebo for Asthma Control, Lung Function Gains
11/22/2021
Researchers investigated itepekimab and dupilumab monotherapies, as well as the combination of both agents, to determine the treatments’ efficacy in patients with asthma.
Researchers investigated itepekimab and dupilumab monotherapies, as well as the combination of both agents, to determine the treatments’ efficacy in patients with asthma.
Researchers investigated...
11/22/2021
First Report Managed Care
News
Pain Medication Recalled
12/16/2021
Prescription opioid tablets are under a Class II recall due to a product mix-up.
Prescription opioid tablets are under a Class II recall due to a product mix-up.
Prescription opioid tablets are...
12/16/2021
Pharmacy Learning Network
News
Eye Solution Recalled
01/13/2022
Eye solution is under a Class III recall for failing to meet stability specifications.
Eye solution is under a Class III recall for failing to meet stability specifications.
Eye solution is under a Class...
01/13/2022
Pharmacy Learning Network
News
Once-daily Therapy Improves Motor Function in Types 2 and 3 Spinal Muscular Atrophy
02/14/2022
Once-daily treatment with risdiplam was more efficacious than placebo in improving motor function in patients with types 2 and 3 spinal muscular atrophy, and research is ongoing to determine the drug's long-term efficacy and safety.
Once-daily treatment with risdiplam was more efficacious than placebo in improving motor function in patients with types 2 and 3 spinal muscular atrophy, and research is ongoing to determine the drug's long-term efficacy and safety.
Once-daily treatment with...
02/14/2022
First Report Managed Care
News
Pharmacists Prompted by System-Generated Alerts Dispense More Naloxone Prescriptions
12/22/2021
Pharmacists dispensed more naloxone prescriptions to high-risk patients in response to system-generated mandatory alerts were built into the pharmacy management system.
Pharmacists dispensed more naloxone prescriptions to high-risk patients in response to system-generated mandatory alerts were built into the pharmacy management system.
Pharmacists dispensed more...
12/22/2021
Pharmacy Learning Network

Advertisement

Advertisement

Advertisement

Advertisement

Upcoming Events

December 4 ⁠–⁠ December 5
Great Debates & Updates in Diabetic Foot
December 6 ⁠–⁠ December 7
AIBD logo
December 9 ⁠–⁠ December 11
December 9 ⁠–⁠ December 11
Psych Congress Primary Care Online Series
December 12 ⁠–⁠ December 13
December 14 ⁠–⁠ December 15
February 2 ⁠–⁠ February 5
Western AF Symposium
February 27 ⁠–⁠ March 1
DCLF
March 17 ⁠–⁠ March 19
NP Institute
March 27 ⁠–⁠ March 30
See Full Calendar

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use